Understand why pharmacological potency, toxicological hazard and a PDE/HBEL value are related but not interchangeable concepts.
Potency describes the dose required to produce a pharmacological effect. Hazard describes the inherent capacity to cause harm. A PDE/HBEL is a health-based exposure limit derived from the broader evidence set and therefore should not be treated as a direct synonym for either concept.
Why the distinction matters
A compound can be pharmacologically potent without presenting the same type or severity of toxicological concern as another compound with a similar therapeutic dose.
Hazard exists on a continuum
Modern risk-based approaches avoid binary labels such as ‘highly hazardous’ versus ‘not highly hazardous’ as substitutes for the full toxicological assessment.
How HBEL integrates evidence
The derived limit can be driven by therapeutic pharmacology, adverse clinical effects, non-clinical toxicity, uncertainty or route-specific considerations.
Implications for manufacturing
The numerical HBEL helps determine the level of control required, but the ultimate risk depends on how exposure can occur in the facility.
Frequently asked questions
Is a potent compound automatically highly hazardous?
No. Potency alone does not describe the nature or severity of harm.
Does the PDE measure potency?
Not directly. It is a health-based exposure limit derived from the overall pharmacological and toxicological evidence.
Can two compounds with similar therapeutic doses have different HBELs?
Yes, because their critical effects and uncertainty can differ.
Why avoid binary classifications?
They can hide important differences and do not replace a quantitative health-based assessment.
